What are the CMO’s remaining Mineralys Therapeutics (MLYS) share holdings after these trades?

Following the reported transactions, Dr. Rodman directly holds 63,443 Mineralys common shares. This figure reflects net holdings after exercising stock options for 16,226 shares and selling 22,575 shares across multiple trades during the May 11–13, 2026 period.

Were the Mineralys Therapeutics (MLYS) insider share sales under a Rule 10b5-1 plan?

Yes. The filing states the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Such pre-arranged plans schedule trades in advance, indicating these sales were part of a structured program rather than discretionary market timing.

Mineralys (NASDAQ: MLYS) CMO exercises options, sells 22,575 shares in 10b5-1 plan

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Mineralys Therapeutics Chief Medical Officer David Malcom Rodman reported a series of equity transactions in May. Over May 11–13, 2026, he sold a total of 22,575 shares of Mineralys common stock in open-market trades at weighted-average prices around the high-$20s per share.

On the same dates, he exercised stock options for 16,226 shares at strike prices ranging from $1.08 to $16.00 per share, converting option awards into common stock. After these transactions, he directly held 63,443 shares of common stock. The filing notes that these sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on October 6, 2025, indicating they were scheduled in advance rather than timed discretionarily.

Insights

Routine plan-based option exercises and sales with net share reduction.

The transactions show Dr. Rodman exercising 16,226 stock options at strike prices between $1.08 and $16.00, then selling 22,575 shares in open-market trades around the high-$20s. This pattern is typical of executives converting options into cash.

The filing states these trades were executed under a Rule 10b5-1 trading plan adopted on October 6, 2025, suggesting they were pre-scheduled rather than opportunistic. After the transactions, he holds 63,443 common shares, so the sales represent only part of his position.

Given the plan-based nature and the remaining holdings, these appear to be routine liquidity and portfolio-management moves rather than a clear directional signal about Mineralys Therapeutics’ prospects. The overall impact on the investment thesis is limited.

Insider Trade Summary 10b5-1

Net Seller: 22,575 shares ($652,638)

Net Sell 11 txns

Insider Rodman David Malcom

Role Chief Medical Officer

Sold 22,575 shs ($653K)

Type	Security	Shares	Price	Value
Exercise	Stock Option	3,541	$0.00	--
Exercise	Stock Option	4,166	$0.00	--
Exercise	Common Stock	3,541	$10.20	$36K
Exercise	Common Stock	4,166	$14.25	$59K
Sale	Common Stock	14,056	$28.5849	$402K
Exercise	Stock Option	6,348	$0.00	--
Exercise	Common Stock	6,348	$1.08	$7K
Sale	Common Stock	6,348	$29.3554	$186K
Exercise	Stock Option	2,171	$0.00	--
Exercise	Common Stock	2,171	$16.00	$35K
Sale	Common Stock	2,171	$29.71	$65K

Holdings After Transaction: Stock Option — 116,876 shares (Direct, null); Common Stock — 73,333 shares (Direct, null)

Footnotes (1)

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $29.14 to $29.60. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $28.0900 to $29.0208. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter. The stock option vests in monthly installments over a period of four years, with 1/48th of the total shares underlying the option vesting each one-month period following the date of grant.

Key Figures

Shares sold: 22,575 shares Shares from option exercises: 16,226 shares Holdings after transactions: 63,443 shares +5 more

8 metrics

Shares sold 22,575 shares Open-market sales on May 11–13, 2026

Shares from option exercises 16,226 shares Options exercised May 11–13, 2026

Holdings after transactions 63,443 shares Common stock directly held after May 13, 2026

Sale price example $29.3554 per share Weighted-average price for 6,348 shares sold May 12, 2026

Sale price example $28.5849 per share Weighted-average price for 14,056 shares sold May 13, 2026

Lowest strike price $1.08 per share Stock option exercise into 6,348 shares of common stock

Highest strike price $16.00 per share Stock option exercise into 2,171 shares of common stock

Rule 10b5-1 plan adoption date October 6, 2025 Plan governing reported trades

Key Terms

Rule 10b5-1 trading plan, weighted-average price, stock option, vests in monthly installments, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted-average price financial

"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging..."

stock option financial

"The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date..."

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

vests in monthly installments financial

"The stock option vests in monthly installments over a period of four years, with 1/48th of the total shares..."

open-market sale financial

"transaction_action: open-market sale, transaction_code_description: Sale in open market or private transaction"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

05/13/2026 - 09:42 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rodman David Malcom

(Last)

(First)

(Middle)

150 N. RADNOR CHESTER RD.

SUITE F200

(Street)

RADNOR

PENNSYLVANIA

19087

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Mineralys Therapeutics, Inc. [ MLYS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/11/2026		M⁽¹⁾		2,171	A	$16	71,963	D
Common Stock	05/11/2026		S⁽¹⁾		2,171	D	$29.71	69,792	D
Common Stock	05/12/2026		M⁽¹⁾		6,348	A	$1.08	76,140	D
Common Stock	05/12/2026		S⁽¹⁾		6,348	D	$29.3554⁽²⁾	69,792	D
Common Stock	05/13/2026		M⁽¹⁾		3,541	A	$10.2	73,333	D
Common Stock	05/13/2026		M⁽¹⁾		4,166	A	$14.25	77,499	D
Common Stock	05/13/2026		S⁽¹⁾		14,056	D	$28.5849⁽³⁾	63,443	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option	$16	05/11/2026		M⁽¹⁾			2,171	⁽⁴⁾	02/09/2033	Common Stock	2,171	$0	19,535	D
Stock Option	$1.08	05/12/2026		M⁽¹⁾			6,348	⁽⁴⁾	07/11/2032	Common Stock	6,348	$0	12,698	D
Stock Option	$10.2	05/13/2026		M⁽¹⁾			3,541	⁽⁵⁾	02/13/2035	Common Stock	3,541	$0	116,876	D
Stock Option	$14.25	05/13/2026		M⁽¹⁾			4,166	⁽⁴⁾	02/13/2034	Common Stock	4,166	$0	87,501	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $29.14 to $29.60. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

3. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $28.0900 to $29.0208. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.

4. The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.

5. The stock option vests in monthly installments over a period of four years, with 1/48th of the total shares underlying the option vesting each one-month period following the date of grant.

Remarks:

	/s/ Adam Levy, Attorney-in-fact	05/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Mineralys Therapeutics (MLYS) report for its CMO?

Mineralys Therapeutics’ Chief Medical Officer David Malcom Rodman reported option exercises and share sales. He exercised options for 16,226 common shares and sold 22,575 shares in open-market transactions over May 11–13, 2026, leaving him with 63,443 directly held shares.

How many Mineralys Therapeutics (MLYS) shares did the CMO sell and at what prices?

Dr. Rodman sold 22,575 Mineralys common shares in open-market trades. Weighted-average sale prices were reported in the high-$20s per share, including transactions around $29.36 and $28.58, with detailed price ranges provided in the filing’s weighted-average price footnotes.

How many Mineralys Therapeutics (MLYS) stock options did the CMO exercise?

He exercised options covering 16,226 Mineralys common shares. These exercises occurred on May 11–13, 2026 at strike prices of $1.08, $10.20, $14.25, and $16.00 per share, converting long-term equity awards into directly held stock before subsequent open-market sales.

What were the strike prices of the Mineralys Therapeutics (MLYS) options exercised by the CMO?

The options exercised had strike prices of $1.08, $10.20, $14.25, and $16.00 per share. These options converted into 16,226 common shares in total, reflecting long-term equity compensation awards that vested over time under the company’s stock option terms.